^
Association details:
Biomarker:EGFR mutation
Cancer:Mesothelioma
Drug:IK-930 (TEAD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

2156 - IK-930 is a novel TEAD inhibitor for the treatment of cancers harboring mutations in the Hippo signal transduction pathway

Published date:
03/09/2022
Excerpt:
Daily oral administration of IK-930 resulted in antitumor activity in Hippo-dysregulated mesothelioma xenograft models. In EGFR or KRAS mutated tumors, IK-930 enhanced apoptosis and in vivo antitumor activity in combination with EGFR and MEK inhibitors, respectively.
Secondary therapy:
MEK Inhibitor + THE-349